UCB S.A.

Neupro approved in Japan for Parkinson’s disease and Restless Legs Syndrome

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Neupro® (rotigotine transdermal patch) for the treatment of Parkinson’s disease (PD) and for the symptomatic treatment of moderate-to-severe idiopathic Restless Legs Syndrome (RLS) in adults. In 2002 Otsuka Pharmaceutic ... more

Astellas and UCB announce approval of Cimzia in Japan for the treatment of rheumatoid arthritis

Astellas Pharma Inc. and UCB S.A. announced that UCB Japan has received marketing approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for Cimzia® (certolizumab pegol). Cimzia®, under joint development in Japan, has been approved as a 200 mg syringe for subcutaneous injec ... more

UCB and Proteros expand successful protein x-ray crystallography collaboration

UCB and Proteros biostructures GmbH announced expansion of their ongoing structural biology collaboration to include additional therapeutic areas. Since 2007, Proteros has supported discovery programmes for UCB in the area of immunology, by solving complex unpublished protein structures to ... more

UCB Pharma S.A.

With a unique combination of expertise in biology and chemistry, UCB is a global biopharma focusing on severe diseases in three therapeutic areas - CNS, inflammation and oncology. more

UCB GmbH

UCB, Brussels, Belgium is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflam ... more

UCB de Mexico S.A. de C.V.

UCB, Brussels, Belgium is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflam ... more